Contrast-Enhanced Ultrasound as a Problem-Solving Modality: Tips and Tricks.
Journal
Ultrasound quarterly
ISSN: 1536-0253
Titre abrégé: Ultrasound Q
Pays: United States
ID NLM: 8809459
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
16
4
2022
medline:
11
6
2022
entrez:
15
4
2022
Statut:
epublish
Résumé
Contrast-enhanced ultrasound (CEUS) continues to be an ever-growing tool in radiation-free imaging. While it has been widely used in cardiac imaging, CEUS has only recently become an Food and Drug Administration-approved and viable modality for evaluation of abdominal structures. Ultrasound contrast agents are nontoxic, microbubble-based vascular agents and can be used to reliably assess enhancement patterns of various lesions in real time. In particular, it's non nephrotoxic nature makes CEUS a particularly important tool in renal failure patients requiring serial follow-up. This review provides a comprehensive discussion on the utility of CEUS agents, imaging techniques, comparison with traditional cross-sectional imaging modalities, and its application in diagnosing kidney and liver lesions. This pictorial review is illustrated with cases of renal and hepatic lesions that the practicing radiologist should become familiar with as CEUS becomes increasingly popular.
Identifiants
pubmed: 35426378
doi: 10.1097/RUQ.0000000000000604
pii: 00013644-202206000-00003
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-115Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Furrer MA, Spycher SCJ, Büttiker SM, et al. Comparison of the diagnostic performance of contrast-enhanced ultrasound with that of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging in the evaluation of renal masses: a systematic review and meta-analysis. Eur Urol Oncol . 2020;3(4):464–473.
Chung YE, Kim KW. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography . 2015;34(1):3–18.
Cabassa P, Bipat S, Longaretti L, et al. Liver metastases: sulphur hexafluoride-enhanced ultrasonography for lesion detection: a systematic review. Ultrasound Med Biol . 2010;36(10):1561–1567.
Cantisani V, Ricci P, Erturk M, et al. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue® low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall Med . 2010;31(5):500–505.
Medwin H. Counting bubbles acoustically: a review. Ultrasonics . 1977;15(1):7–13.
Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology . 2010;257(1):24–39.
Baun J. Contrast-enhanced ultrasound: a technology primer. J Diagn Med Sonography . 2017;33(6):446–452.
Qin S, Caskey CF, Ferrara KW. Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Phys Med Biol . 2009;54(6):R27–R57.
Smajerova M, Petrasova H, Little J, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis. World J Gastroenterol . 2016;22(38):8605–8614.
Torzilli G. Adverse effects associated with SonoVue use. Expert Opin Drug Saf . 2005;4(3):399–401.
Levano JA, Jimenez MA, Laiseca A, et al. Anaphylactic shock due to SonoVue. Ann Allergy Asthma Immunol . 2012;108(3):208–209.
Geleijnse ML, Nemes A, Vletter WB, et al. Adverse reactions after the use of sulphur hexafluoride (SonoVue) echo contrast agent. J Cardiovasc Med (Hagerstown) . 2009;10(1):75–77.
Chou YH, Liang JD, Wang SY, et al. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions. J Med Ultrasound . 2019;27(2):81–85.
Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open . 2018;4(1):E2–E15.
Kim KW, Kim TK, Han JK, et al. Hepatic hemangiomas: spectrum of US appearances on gray-scale, power Doppler, and contrast-enhanced US. Korean J Radiol . 2000;1(4):191–197.
Kim TK, Han JK, Kim AY, et al. Signal from hepatic hemangiomas on power Doppler US: real or artefactual? Ultrasound Med Biol . 1999;25(7):1055–1061.
Dietrich CF, Mertens JC, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology . 2007;45(5):1139–1145.
Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol . 2005;78(932):704–707.
Bischof DA, Choti MA. Differential diagnoses and diagnostic troubleshooting of upper abdominal masses. Gastroenterol Hepatol (N Y) . 2013;9(6):399–400.
Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol . 2005;39(5):401–412.
Jang HJ, Yu H, Kim TK. Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging . 2009;9(1):96–103.
Venturi A, Piscaglia F, Vidili G, et al. Diagnosis and management of hepatic focal nodular hyperplasia. J Ultrasound . 2007;10(3):116–127.
Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology . 2000;216(2):395–402.
Molina EGSE. Benign solid lesions of the liver. In: Schiff ERSM, Maddrey WC, eds. Schiff's Diseases of the Liver . 8th ed. Philadelphia: Lippincott-Raven; 1999:1245–1267.
Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics . 2001;21(4):877–892.
Kim TK, Jang HJ, Burns PN, et al. Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. Am J Roentgenol . 2008;190(1):58–66.
Wang W, Liu JY, Yang Z, et al. Hepatocellular adenoma: comparison between real-time contrast-enhanced ultrasound and dynamic computed tomography. Springerplus . 2016;5(1):951.
Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma . 2016;3:41–53.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer . 2010;127(12):2893–2917.
Soresi M, Terranova A, Licata A, et al. Surveillance program for diagnosis of HCC in liver cirrhosis: role of ultrasound echo patterns. Biomed Res Int . 2017;2017:4932759.
Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) . 2005;7(1):35–41.
Jang HJ, Kim TK, Burns PN, et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology . 2007;244(3):898–906.
Kim TK, Noh SY, Wilson SR, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017—a review of important differences compared to the CT/MRI system. Clin Mol Hepatol . 2017;23(4):280–289.
Piscaglia F, Wilson SR, Lyshchik A, et al. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of hepatocellular carcinoma: a pictorial essay. Ultraschall Med . 2017;38(3):320–324.
Bansal S, Gui J, Merrill C, et al. Contrast-enhanced US in local ablative therapy and secondary surveillance for hepatocellular carcinoma. Radiographics . 2019;39(5):1302–1322.
Tarantino L, Francica G, Sordelli I, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging . 2006;31(5):537–544.
Tamai H, Takiguchi Y, Oka M, et al. Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J Ultrasound Med . 2005;24(12):1635–1640.
Sanz E, Hevia V, Gómez V, et al. Renal complex cystic masses: usefulness of contrast-enhanced ultrasound (CEUS) in their assessment and its agreement with computed tomography. Curr Urol Rep . 2016;17(12):89.
Bosniak MA. The current radiological approach to renal cysts. Radiology . 1986;158(1):1–10.
Zhou X, Yan F, Luo Y, et al. Characterization and diagnostic confidence of contrast-enhanced ultrasound for solid renal tumors. Ultrasound Med Biol . 2011;37(6):845–853.
Gulati M, King KG, Gill IS, et al. Contrast-enhanced ultrasound (CEUS) of cystic and solid renal lesions: a review. Abdom Imaging . 2015;40(6):1982–1996.
Mazziotti S, Cicero G, D'Angelo T, et al. Imaging and management of incidental renal lesions. Biomed Res Int . 2017;2017:1854027.
Xu ZF, Xu HX, Xie XY, et al. Renal cell carcinoma: real-time contrast-enhanced ultrasound findings. Abdom Imaging . 2010;35(6):750–756.
Cokkinos DD, Antypa EG, Skilakaki M, et al. Contrast enhanced ultrasound of the kidneys: what is it capable of? Biomed Res Int . 2013;2013:595873.
O'Neal D, Cohen T, Peterson C, et al. Contrast-enhanced ultrasound-guided radiofrequency ablation of renal tumors. J Kidney Cancer VHL . 2018;5(1):7–14.
Piscaglia F, Nolsøe C, Dietrich CF, et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med . 2012;33(1):33–59.
Bai Y. Recurrence of renal cell cancers after thermal ablation. Radiology . 2017;285(3):1061–1063.
Zagoria RJ, Pettus JA, Rogers M, et al. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology . 2011;77(6):1393–1397.
Kong WT, Zhang WW, Guo HQ, et al. Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response? Abdom Imaging . 2011;36(3):342–347.
Hoeffel C, Pousset M, Timsit MO, et al. Radiofrequency ablation of renal tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual tumour. Eur Radiol . 2010;20(8):1812–1821.
Lumason® (Sulfur Hexafluoride Lipid-Type A Microspheres) [package insert] . Monroe Township, NJ: Bracco Diagnostics Inc; 2020.
Piscaglia F, Bolondi L; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The safety of SonoVue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol . 2006;32(9):1369–1375.
Tang C, Fang K, Guo Y, et al. Safety of sulfur hexafluoride microbubbles in sonography of abdominal and superficial organs: retrospective analysis of 30,222 cases. J Ultrasound Med . 2017;36(3):531–538.
Anantharam B, Chahal N, Chelliah R, et al. Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin. Am J Cardiol . 2009;104(1):14–18.
Muskula PR, Main ML. Safety with echocardiographic contrast agents. Circ Cardiovasc Imaging . 2017;10(4):e005459.
Barr RG. How to develop a contrast-enhanced ultrasound program. J Ultrasound Med . 2017;36:1225–1240.